Build Your Comparison

Side-by-side financial analysis
TOI logo
TOI
AIOT logo
AIOT
ONCO logo
ONCO
USPH logo
USPH
OPCH logo
OPCH
Try popular comparisons:

Stock Comparison

TOI vs AIOT vs ONCO vs USPH vs OPCH

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
TOI
The Oncology Institute, Inc.

Medical - Care Facilities

HealthcareNASDAQ • US
Market Cap$5.41B
5Y Perf.+1054.3%
AIOT
PowerFleet, Inc.

Communication Equipment

TechnologyNASDAQ • US
Market Cap$574M
5Y Perf.-7.7%
ONCO
Onconetix, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$654K
5Y Perf.-100.0%
USPH
U.S. Physical Therapy, Inc.

Medical - Care Facilities

HealthcareNYSE • US
Market Cap$999M
5Y Perf.-29.1%
OPCH
Option Care Health, Inc.

Medical - Care Facilities

HealthcareNASDAQ • US
Market Cap$3.25B
5Y Perf.-25.1%

TOI vs AIOT vs ONCO vs USPH vs OPCH — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
TOI logoTOI
AIOT logoAIOT
ONCO logoONCO
USPH logoUSPH
OPCH logoOPCH
IndustryMedical - Care FacilitiesCommunication EquipmentBiotechnologyMedical - Care FacilitiesMedical - Care Facilities
Market Cap$5.41B$574M$654K$999M$3.25B
Revenue (TTM)$546M$436M$735K$695M$5.67B
Net Income (TTM)$-44M$-32M$-10M$11M$206M
Gross Margin14.8%55.2%79.6%22.0%18.0%
Operating Margin-6.0%1.7%-9.2%12.5%5.9%
Forward P/E22.6x11.3x
Total Debt$104M$287M$49K$426M$0.00
Cash & Equiv.$34M$49M$5M$36M$233M

TOI vs AIOT vs ONCO vs USPH vs OPCHLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

TOI
AIOT
ONCO
USPH
OPCH
StockJun 24Jun 26Return
The Oncology Instit… (TOI)1001154.3+1054.3%
PowerFleet, Inc. (AIOT)10092.3-7.7%
Onconetix, Inc. (ONCO)1000.0-100.0%
U.S. Physical Thera… (USPH)10070.9-29.1%
Option Care Health,… (OPCH)10074.9-25.1%

Price return only. Dividends and distributions are not included.

Quick Verdict: TOI vs AIOT vs ONCO vs USPH vs OPCH

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: OPCH leads in 4 of 7 categories (5-stock set), making it the strongest pick for valuation and capital efficiency and profitability and margin quality. PowerFleet, Inc. is the stronger pick specifically for growth and revenue expansion and dividend income and shareholder returns. TOI also leads in specific categories worth noting. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
🥇OPCH emerged as the overall leader. Track its performance:
TOI
The Oncology Institute, Inc.
The Momentum Pick

TOI ranks third and is worth considering specifically for momentum.

  • +100.4% vs ONCO's -99.7%
Best for: momentum
AIOT
PowerFleet, Inc.
The Growth Play

AIOT is the #2 pick in this set and the best alternative if growth exposure is your priority.

  • Rev growth 66.3%, EPS growth 60.6%, 3Y rev CAGR 42.2%
  • 66.3% revenue growth vs ONCO's -67.7%
  • 17.8% yield, 1-year raise streak, vs USPH's 2.8%, (3 stocks pay no dividend)
Best for: growth exposure
ONCO
Onconetix, Inc.
The Healthcare Pick

ONCO lags the leaders in this set but could rank higher in a more targeted comparison.

Best for: healthcare exposure
USPH
U.S. Physical Therapy, Inc.
The Income Pick

USPH is the clearest fit if your priority is income & stability.

  • Dividend streak 15 yrs, beta 0.89, yield 2.8%
Best for: income & stability
OPCH
Option Care Health, Inc.
The Long-Run Compounder

OPCH carries the broadest edge in this set and is the clearest fit for long-term compounding and sleep-well-at-night.

  • 127.6% 10Y total return vs USPH's 33.5%
  • Lower volatility, beta 0.29, current ratio 1.53x
  • Beta 0.29, current ratio 1.53x
  • Lower P/E (11.3x vs 22.6x)
Best for: long-term compounding and sleep-well-at-night
See the full category breakdown
CategoryWinnerWhy
GrowthAIOT logoAIOT66.3% revenue growth vs ONCO's -67.7%
ValueOPCH logoOPCHLower P/E (11.3x vs 22.6x)
Quality / MarginsOPCH logoOPCH3.6% margin vs ONCO's -13.2%
Stability / SafetyOPCH logoOPCHBeta 0.29 vs AIOT's 2.71
DividendsAIOT logoAIOT17.8% yield, 1-year raise streak, vs USPH's 2.8%, (3 stocks pay no dividend)
Momentum (1Y)TOI logoTOI+100.4% vs ONCO's -99.7%
Efficiency (ROA)OPCH logoOPCH6.0% ROA vs ONCO's -49.4%, ROIC 15.3% vs -32.8%

TOI vs AIOT vs ONCO vs USPH vs OPCH — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

TOIThe Oncology Institute, Inc.
FY 2025
Health Care, Patient Service
49.5%$229M
Fee For Service
32.1%$149M
Capitated Revenue
17.4%$80M
Clinical Research Trials And Other Revenue
1.0%$5M
AIOTPowerFleet, Inc.
FY 2024
Service
62.8%$84M
Product
37.2%$50M
ONCOOnconetix, Inc.
FY 2025
License
0.0%$0
USPHU.S. Physical Therapy, Inc.
FY 2025
Net Patient Revenues
83.3%$650M
Other Revenues Including Management Contract Revenues and Industrial Injury Prevention Services Revenues
16.7%$131M
OPCHOption Care Health, Inc.
FY 2025
Reportable Segment
100.0%$5.6B

TOI vs AIOT vs ONCO vs USPH vs OPCH — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLOPCHLAGGINGUSPH

Income & Cash Flow (Last 12 Months)

Evenly matched — ONCO and USPH each lead in 2 of 6 comparable metrics.

OPCH is the larger business by revenue, generating $5.7B annually — 7708.4x ONCO's $735,198. OPCH is the more profitable business, keeping 3.6% of every revenue dollar as net income compared to ONCO's -13.2%. On growth, AIOT holds the edge at +47.4% YoY revenue growth, suggesting stronger near-term business momentum.

MetricTOI logoTOIThe Oncology Inst…AIOT logoAIOTPowerFleet, Inc.ONCO logoONCOOnconetix, Inc.USPH logoUSPHU.S. Physical The…OPCH logoOPCHOption Care Healt…
RevenueTrailing 12 months$546M$436M$735,198$695M$5.7B
EBITDAEarnings before interest/tax-$26M$69M-$7M$109M$406M
Net IncomeAfter-tax profit-$44M-$32M-$10M$11M$206M
Free Cash FlowCash after capex-$26M$3M-$10M$67M$244M
Gross MarginGross profit ÷ Revenue+14.8%+55.2%+79.6%+22.0%+18.0%
Operating MarginEBIT ÷ Revenue-6.0%+1.7%-9.2%+12.5%+5.9%
Net MarginNet income ÷ Revenue-8.0%-7.4%-13.2%+1.5%+3.6%
FCF MarginFCF ÷ Revenue-4.7%+0.6%-13.3%+9.6%+4.3%
Rev. Growth (YoY)Latest quarter vs prior year+41.2%+47.4%-78.9%+7.7%+1.3%
EPS Growth (YoY)Latest quarter vs prior year+90.5%-25.5%+98.7%-115.0%+3.6%
Evenly matched — ONCO and USPH each lead in 2 of 6 comparable metrics.

Valuation Metrics

OPCH leads this category, winning 4 of 6 comparable metrics.

At 16.3x trailing earnings, OPCH trades at a 65% valuation discount to USPH's 46.2x P/E. On an enterprise value basis, OPCH's 7.4x EV/EBITDA is more attractive than AIOT's 51.2x.

MetricTOI logoTOIThe Oncology Inst…AIOT logoAIOTPowerFleet, Inc.ONCO logoONCOOnconetix, Inc.USPH logoUSPHU.S. Physical The…OPCH logoOPCHOption Care Healt…
Market CapShares × price$5.4B$574M$653,669$999M$3.2B
Enterprise ValueMkt cap + debt − cash$5.5B$813M-$5M$1.4B$3.0B
Trailing P/EPrice ÷ TTM EPS-9.83x-9.81x-0.22x46.17x16.35x
Forward P/EPrice ÷ next-FY EPS est.22.64x11.31x
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple51.19x13.51x7.38x
Price / SalesMarket cap ÷ Revenue10.75x1.58x0.80x1.28x0.57x
Price / BookPrice ÷ Book value/share1.13x0.22x1.29x2.56x
Price / FCFMarket cap ÷ FCF16.37x12.57x
OPCH leads this category, winning 4 of 6 comparable metrics.

Profitability & Efficiency

OPCH leads this category, winning 7 of 9 comparable metrics.

OPCH delivers a 15.3% return on equity — every $100 of shareholder capital generates $15 in annual profit, vs $-105 for ONCO. ONCO carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to AIOT's 0.64x. On the Piotroski fundamental quality scale (0–9), ONCO scores 5/9 vs AIOT's 3/9, reflecting solid financial health.

MetricTOI logoTOIThe Oncology Inst…AIOT logoAIOTPowerFleet, Inc.ONCO logoONCOOnconetix, Inc.USPH logoUSPHU.S. Physical The…OPCH logoOPCHOption Care Healt…
ROE (TTM)Return on equity-6.6%-105.5%+1.4%+15.3%
ROA (TTM)Return on assets-26.5%-3.4%-49.4%+0.9%+6.0%
ROICReturn on invested capital-41.2%-4.3%-32.8%+5.6%+15.3%
ROCEReturn on capital employed-33.7%-5.1%-49.4%+7.6%+12.8%
Piotroski ScoreFundamental quality 0–943555
Debt / EquityFinancial leverage0.64x0.00x0.55x
Net DebtTotal debt minus cash$70M$238M-$5M$390M-$233M
Cash & Equiv.Liquid assets$34M$49M$5M$36M$233M
Total DebtShort + long-term debt$104M$287M$48,774$426M$0
Interest CoverageEBIT ÷ Interest expense-4.96x0.47x-17.32x8.24x5.50x
OPCH leads this category, winning 7 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

TOI leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in OPCH five years ago would be worth $10,112 today (with dividends reinvested), compared to $0 for ONCO. Over the past 12 months, TOI leads with a +100.4% total return vs ONCO's -99.7%. The 3-year compound annual growth rate (CAGR) favors TOI at 111.1% vs ONCO's -98.0% — a key indicator of consistent wealth creation.

MetricTOI logoTOIThe Oncology Inst…AIOT logoAIOTPowerFleet, Inc.ONCO logoONCOOnconetix, Inc.USPH logoUSPHU.S. Physical The…OPCH logoOPCHOption Care Healt…
YTD ReturnYear-to-date+44.7%-19.6%-98.7%-15.7%-35.6%
1-Year ReturnPast 12 months+100.4%-11.0%-99.7%-13.8%-34.9%
3-Year ReturnCumulative with dividends+841.3%-11.5%-100.0%-35.5%-30.9%
5-Year ReturnCumulative with dividends-47.4%-11.5%-100.0%-37.8%+1.1%
10-Year ReturnCumulative with dividends-45.3%-11.5%-100.0%+33.5%+127.6%
CAGR (3Y)Annualised 3-year return+111.1%-4.0%-98.0%-13.6%-11.6%
TOI leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

Evenly matched — TOI and OPCH each lead in 1 of 2 comparable metrics.

OPCH is the less volatile stock with a 0.29 beta — it tends to amplify market swings less than AIOT's 2.71 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. TOI currently trades 95.2% from its 52-week high vs ONCO's 0.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricTOI logoTOIThe Oncology Inst…AIOT logoAIOTPowerFleet, Inc.ONCO logoONCOOnconetix, Inc.USPH logoUSPHU.S. Physical The…OPCH logoOPCHOption Care Healt…
Beta (5Y)Sensitivity to S&P 5001.95x2.71x1.33x0.89x0.29x
52-Week HighHighest price in past year$5.58$5.88$361.50$93.50$36.80
52-Week LowLowest price in past year$2.02$2.77$0.91$58.19$18.01
% of 52W HighCurrent price vs 52-week peak+95.2%+71.8%+0.3%+70.1%+56.4%
RSI (14)Momentum oscillator 0–10065.365.925.153.544.1
Avg Volume (50D)Average daily shares traded1.6M1.5M1.4M199K3.2M
Evenly matched — TOI and OPCH each lead in 1 of 2 comparable metrics.

Analyst Outlook

Evenly matched — AIOT and USPH each lead in 1 of 2 comparable metrics.

Analyst consensus: TOI as "Buy", AIOT as "Buy", USPH as "Buy", OPCH as "Buy". Consensus price targets imply 89.6% upside for AIOT (target: $8) vs 46.4% for USPH (target: $96). For income investors, AIOT offers the higher dividend yield at 17.85% vs USPH's 2.75%.

MetricTOI logoTOIThe Oncology Inst…AIOT logoAIOTPowerFleet, Inc.ONCO logoONCOOnconetix, Inc.USPH logoUSPHU.S. Physical The…OPCH logoOPCHOption Care Healt…
Analyst RatingConsensus buy/hold/sellBuyBuyBuyBuy
Price TargetConsensus 12-month target$8.00$8.00$96.00$31.22
# AnalystsCovering analysts551314
Dividend YieldAnnual dividend ÷ price+17.8%+2.8%
Dividend StreakConsecutive years of raises10151
Dividend / ShareAnnual DPS$0.75$1.80
Buyback YieldShare repurchases ÷ mkt cap0.0%+0.5%0.0%+0.6%+9.5%
Evenly matched — AIOT and USPH each lead in 1 of 2 comparable metrics.
Key Takeaway

OPCH leads in 2 of 6 categories (Valuation Metrics, Profitability & Efficiency). TOI leads in 1 (Total Returns). 3 tied.

Best OverallOption Care Health, Inc. (OPCH)Leads 2 of 6 categories
Loading custom metrics...

TOI vs AIOT vs ONCO vs USPH vs OPCH: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is TOI or AIOT or ONCO or USPH or OPCH a better buy right now?

For growth investors, The Oncology Institute, Inc.

(TOI) is the stronger pick with 27. 8% revenue growth year-over-year, versus -67. 7% for Onconetix, Inc. (ONCO). Option Care Health, Inc. (OPCH) offers the better valuation at 16. 3x trailing P/E (11. 3x forward), making it the more compelling value choice. Analysts rate The Oncology Institute, Inc. (TOI) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — TOI or AIOT or ONCO or USPH or OPCH?

On trailing P/E, Option Care Health, Inc.

(OPCH) is the cheapest at 16. 3x versus U. S. Physical Therapy, Inc. at 46. 2x. On forward P/E, Option Care Health, Inc. is actually cheaper at 11. 3x.

03

Which is the better long-term investment — TOI or AIOT or ONCO or USPH or OPCH?

Over the past 5 years, Option Care Health, Inc.

(OPCH) delivered a total return of +1. 1%, compared to -100. 0% for Onconetix, Inc. (ONCO). Over 10 years, the gap is even starker: OPCH returned +127. 6% versus ONCO's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — TOI or AIOT or ONCO or USPH or OPCH?

By beta (market sensitivity over 5 years), Option Care Health, Inc.

(OPCH) is the lower-risk stock at 0. 29β versus PowerFleet, Inc. 's 2. 71β — meaning AIOT is approximately 843% more volatile than OPCH relative to the S&P 500. On balance sheet safety, Onconetix, Inc. (ONCO) carries a lower debt/equity ratio of 0% versus 64% for PowerFleet, Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — TOI or AIOT or ONCO or USPH or OPCH?

By revenue growth (latest reported year), The Oncology Institute, Inc.

(TOI) is pulling ahead at 27. 8% versus -67. 7% for Onconetix, Inc. (ONCO). On earnings-per-share growth, the picture is similar: Onconetix, Inc. grew EPS 99. 1% year-over-year, compared to -22. 8% for U. S. Physical Therapy, Inc.. Over a 3-year CAGR, AIOT leads at 42. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — TOI or AIOT or ONCO or USPH or OPCH?

Option Care Health, Inc.

(OPCH) is the more profitable company, earning 3. 7% net margin versus -1721. 0% for Onconetix, Inc. — meaning it keeps 3. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: USPH leads at 10. 3% versus -778. 2% for ONCO. At the gross margin level — before operating expenses — ONCO leads at 77. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is TOI or AIOT or ONCO or USPH or OPCH more undervalued right now?

On forward earnings alone, Option Care Health, Inc.

(OPCH) trades at 11. 3x forward P/E versus 22. 6x for U. S. Physical Therapy, Inc. — 11. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for AIOT: 89. 6% to $8. 00.

08

Which pays a better dividend — TOI or AIOT or ONCO or USPH or OPCH?

In this comparison, AIOT (17.

8% yield), USPH (2. 8% yield) pay a dividend. TOI, ONCO, OPCH do not pay a meaningful dividend and should not be held primarily for income.

09

Is TOI or AIOT or ONCO or USPH or OPCH better for a retirement portfolio?

For long-horizon retirement investors, Option Care Health, Inc.

(OPCH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 29), +127. 6% 10Y return). The Oncology Institute, Inc. (TOI) carries a higher beta of 1. 95 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (OPCH: +127. 6%, TOI: -45. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between TOI and AIOT and ONCO and USPH and OPCH?

These companies operate in different sectors (TOI (Healthcare) and AIOT (Technology) and ONCO (Healthcare) and USPH (Healthcare) and OPCH (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: TOI is a small-cap high-growth stock; AIOT is a small-cap income-oriented stock; ONCO is a small-cap quality compounder stock; USPH is a small-cap high-growth stock; OPCH is a small-cap deep-value stock. AIOT, USPH pay a dividend while TOI, ONCO, OPCH do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.